Srs Therapeutics Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
as on 12-12-2024
- Paid Up Capital ₹ 0.10 M
as on 12-12-2024
- Company Age 18 Year, 9 Months
- Last Filing with ROC 31 Mar 2021
- Revenue 661.31%
(FY 2021)
- Profit -387.17%
(FY 2021)
- Ebitda -249.47%
(FY 2021)
- Net Worth -7.72%
(FY 2021)
- Total Assets -12.54%
(FY 2021)
About Srs Therapeutics
The Corporate was formerly known as Yeva Therapeutics Private Limited. The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2021. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Suchet Rastogi and Rajan Dubey serve as directors at the Company.
- CIN/LLPIN
U85191MH2006PTC161490
- Company No.
161490
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
28 Apr 2006
- Date of AGM
19 Aug 2021
- Date of Balance Sheet
31 Mar 2021
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Company Details
- Location
Mumbai, Maharashtra, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Srs Therapeutics?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Suchet Rastogi  | Director | 28-Apr-2006 | Current |
| Rajan Dubey | Director | 06-Feb-2020 | Current |
Financial Performance of Srs Therapeutics.
Srs Therapeutics Private Limited, for the financial year ended 2021, experienced significant growth in revenue, with a 661.31% increase. The company also saw a substantial fall in profitability, with a 387.17% decrease in profit. The company's net worth dipped by a decrease of 7.72%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Srs Therapeutics?
In 2021, Srs Therapeutics had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Srs Unistraw Private LimitedActive 19 years 11 monthsSuchet Rastogi and Rajan Dubey are mutual person
- Clesstra Healthcare Private LimitedActive 19 years 11 months
Suchet Rastogi and Rajan Dubey are mutual person
- Unitex Tenamyd Canada Private LimitedActive 18 years 7 months
Suchet Rastogi and Rajan Dubey are mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Srs Therapeutics?
Unlock and access historical data on people associated with Srs Therapeutics, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Srs Therapeutics, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Srs Therapeutics's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
